Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclopharm Limited (AU:CYC)
ASX:CYC
CYC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$1.33 - AU$2.50
Previous CloseN/A
Volume20.15K
Average Volume (3M)158.07K
Market Cap
AU$214.49M
Enterprise ValueAU$140.01M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 01, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding111,136,850
10 Day Avg. Volume124,369
30 Day Avg. Volume158,069
Standard Deviation0.18
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.14
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Cyclopharm Limited News
PremiumCompany Announcements
Cyclopharm Substantial Shareholder Interest Update
PremiumCompany Announcements
Cyclopharm Responds to ASX Inquiry on Share Trading Surge
PremiumCompany Announcements
Cyclopharm Expands Technegas Footprint in U.S. Market
PremiumCompany Announcements
Cyclopharm: Technegas Poised for US Market Breakthrough
PremiumCompany Announcements
Cyclopharm’s Technegas Advances Pulmonary Embolism Diagnostics
PremiumCompany Announcements
Cyclopharm Secures Key Orders from US VA Hospitals
PremiumCompany Announcements
Cyclopharm Limited Shares Future Financial Outlook
PremiumCompany Announcements
Cyclopharm Secures Deal with US Veterans Administration---
Options Prices
Currently, No data available
---
Ownership Overview
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$1.33 and its highest was AU$2.50 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$214.49M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Aug 20, 2025 which is in 179 days.
How were Cyclopharm Limited’s earnings last quarter?
Currently, no data Available
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Annually dividend of AU$0.004 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 111,136,850 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
---
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYC Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.13%
12-Months-Change
Fundamentals
Return on Equity
-22.59%
Trailing 12-Months
Asset Growth
29.98%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
---
CYC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cochlear Limited
―
CSL
―
Nanosonics Limited
―
PYC Therapeutics Limited
―
Resonance Health Ltd
―
Best Analysts Covering CYC
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-18.40%
reiterated a buy rating 6 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -18.40% per trade.
---